The main driver of the past two weeks remains the growing dollar index, which...
The American pharmaceutical sector appears to be a unique collection of investment ideas. We have been paying a lot of attention to pharma lately, and for good reason. As the results of 2022 show, the sector is growing well with a general downward trend.
Vertex Pharmaceuticals is another bright representative of the biotechnological direction.
Business strengths:
Risks:
Vertex has no obvious competitors with the same line of active drugs for the treatment of autosomal disease.
The financial performance of Vertex Pharmaceuticals – we have data for the third quarter of 2022 – looks very good. Revenue for the reporting period increased by 17.7% YoY, quarterly adjusted profit +9% YoY, EPS – $4.01 (+$0.37 above expectations).
The consensus forecast for Vertex Pharmaceuticals shares for the next 12 months is $345.
The daily trading schedule of the company’s securities is cautious. The MACD indicator has descended into the negative zone, signaling a sale, but the potential seems to be exhausted. The Stohastic oscillator exits the oversold zone and forms a buy signal.
The main driver of the past two weeks remains the growing dollar index, which...
ES (S&P 500) S&P 500 correction is over. We not only managed to make ...
ES (S&P 500) Correction has begun for the S&P 500. We took a position...
Over the past two weeks, the broad market has remained at its highs without a...